Volume 3.29 | Jul 24

Hematopoiesis News 3.29 July 24, 2012
Hematopoiesis News
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
Noncanonical Wnt Signaling Maintains Hematopoietic Stem Cells in the Niche
Scientists demonstrated that noncanonical Wnt signaling maintains quiescent long-term hematopoietic stem cells through flamingo and frizzled 8 interaction in the niche. [Cell] Abstract | Press Release

Complimentary Wallchart: Human Hematopoietic Progenitors. Request Your Copy Today.
PUBLICATIONS (Ranked by impact factor of the journal)


The Origin and Evolution of Mutations in Acute Myeloid Leukemia
To better understand clonal evolution in acute myeloid leukemia (AML), researchers sequenced the genomes of M3-AML samples with a known initiating event versus the genomes of normal karyotype M1-AML samples and the exomes of hematopoietic stem/progenitor cells from healthy people. [Cell] Abstract | Press Release

Hematopoietic Stem Cell Development Requires Transient Wnt/β-Catenin Activity
Investigators suggest that Wnt/β-catenin activity is transiently required in the aorta-gonad-mesonephros (AGM) to generate long-term hematopoietic stem cells and to produce hematopoietic cells in vitro from AGM endothelial precursors. [J Exp Med] Abstract

Spliceosomal Gene Mutations Are Frequent Events in the Diverse Mutational Spectrum of Chronic Myelomonocytic Leukemia but Largely Absent in Juvenile Myelomonocytic Leukemia
Scientists investigated the contribution of U2AF1, SRSF2 and SF3B1 mutations in the pathogenesis of chronic myelomonocytic leukemia and the closely related diseases. [Haematologica] Abstract | Full Article

Dlk1 Is a Negative Regulator of Emerging Hematopoietic Stem and Progenitor Cells
Researchers studied delta-like homologue 1 (Dlk1) expression in wild-type and hematopoietic stem cell-deficient embryos and determined hematopoietic stem and progenitor cell activity in Dlk1 knockout and overexpressing mice. The role of Dlk1 in hematopoietic support was studied in co-culture experiments using stromal cell lines that express varying levels of Dlk1. [Haematologica] Abstract

Reduced Repression of Cytokine Signaling Ameliorates Age-Induced Decline in Hematopoietic Stem Cell Function
Scientists suggest that enhanced cytokine signaling can counteract functional age-related hematopoietic stem cell decline. [Aging Cell] Abstract

A Novel Complex, RUNX1- MYEF2, Represses Hematopoietic Genes in Erythroid Cells
A tagging strategy was used to show that RUNX1 interacts with two novel protein partners, LSD1 and MYEF2, in erythroid cells. Functional analysis showed that a subset of the target genes is suppressed by RUNX1 via the newly identified partner MYEF2. Knock down of Myef2 expression in developing zebrafish resulted in a reduced number of hematopoietic stem cells. [Mol Cell Biol] Abstract

Human Embryonic Stem Cell-Derived Hematopoietic Cells Maintain Core Epigenetic Machinery of the PcG/TrxG Complexes Distinctly from Functional Adult Hematopoietic Stem Cells
Investigators revealed that human embryonic stem cell-derived hematopoietic progenitor cells fail to express critical transcription factors known to govern self-renewal and myeloid/lymphoid development, and instead retain expression of polycomb group (PcG) and trithorax group (TrxG) factors more prevalent in embryonic cell types. [Stem Cells Dev] Abstract

Infusion of Endothelial Progenitor Cells Accelerates Hematopoietic and Immune Reconstitution, and Ameliorates the Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation
Scientists demonstrated that infusion of endothelial progenitor cells augments the hematopoietic and immune reconstitution, and alleviates the graft-versus-host disease. [Cell Biochem Biophys] Abstract

SAP30L (Sin3A-Associated Protein 30-Like) Is Involved in Regulation of Cardiac Development and Hematopoiesis in Zebrafish Embryos
Researchers demonstrated that SAP30L regulates several transcriptional pathways in zebrafish embryos and is involved in the development of cardiac and hematopoietic systems. [J Cell Biochem] Abstract


A Phase I/II Study of Decitabine in Patients with Myelodysplastic Syndrome
Researchers performed a phase I/II study to evaluate the safety and efficacy of decitabine in patients with myelodysplastic syndrome. [Cancer Sci] Abstract

FLAG-Amsacrine: An Effective Salvage Therapy Option for Acute Myeloid Leukemia at First Relapse
Scientists presented a cohort of 58 patients treated with fludarabine, cytarabine, G-CSF and amsacrine (FLAG-amsacrine) as salvage chemotherapy for acute myeloid leukemia at first relapse. [Leuk Lymphoma] Abstract

Visit the Human Immunology Portal for cord blood protocols, tips and other resources.

AMAG Pharmaceuticals Announces Positive Preliminary Results from Its Phase III Study Evaluating Feraheme Compared to Placebo in Patients with Iron Deficiency Anemia
AMAG Pharmaceuticals, Inc. reported preliminary results from the second phase III study from its global registrational program for Feraheme® (ferumoxytol) in patients with iron deficiency anemia regardless of the underlying cause. [AMAG Pharmaceuticals, Inc.] Press Release | Webcast

CMX001 Demonstrates Potential to Mitigate BK Virus Associated End-Organ Disease in Clinical Study
Chimerix, Inc. announced that its CMX001 has the potential to reduce end-organ damage associated with BK virus in hematopoietic stem cell transplant recipients. [Press release from Chimerix, Inc. discussing research presented at the 24th International Congress of the Transplantation Society, Berlin] Press Release

First Subjects Enrolled in Phase IIa Clinical Trial of EPODURE Biopumps to Treat Anemia in Patients with End-Stage Renal Disease on Dialysis
Medgenics, Inc. announced the launch of its Phase IIa clinical trial in Israel of EPODURE™ Biopumps to treat anemia in patients with end-stage renal disease on dialysis, through the sustained delivery of erythropoietin. [Medgenics, Inc.] Press Release

Actinium Pharmaceuticals Successfully Completes First Cohort in Multicenter Phase I/II Leukemia Trial of Actimab-A™
Actinium Pharmaceuticals, Inc. announced that it has successfully treated the first cohort of patients in a Phase I/II study of Actimab-A™ in Acute Myeloid Leukemia clinical trial. [PR Newswire Association LLC] Press Release

New Clinical Trial Seeks to Cure Advanced Crohn’s Disease by Replacing a Diseased Immune System with a Healthy One
Researchers at Fred Hutchinson Cancer Research Center have opened a clinical trial to test the theory that giving a patient a new immune system can cure severe cases of Crohn’s disease. The initial goal of the Crohn’s Allogeneic Transplant Study is to treat a small number of patients with treatment-resistant Crohn’s disease by transplanting matched bone marrow cells from a sibling or unrelated donor. [Fred Hutchinson Cancer Research Center] Press Release

Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
Trovagene, Inc. received notice of U.S. Patent 8,222,370. This is the first U.S. patent issued around nucleophosmin protein (NPM) mutations, and is part of a family of filed patents for Trovagene around NPMs. Mutation analysis of NPM1 is currently used for the diagnosis, stratification and monitoring of patients with acute myeloid leukemia. [PR Newswire Association LLC] Press Release

Infinity Regains Worldwide Rights to PI3K, FAAH and Early Discovery Programs
Infinity Pharmaceuticals, Inc. announced it has restructured its strategic alliance with Mundipharma International Corporation Limited and Purdue Pharmaceutical Products L.P. by mutual agreement. With this restructuring, Infinity regains worldwide rights for its phosphoinositide-3-kinase (PI3K) program, its fatty acid amide hydrolase (FAAH) program and its early discovery programs. [Infinity Pharmaceuticals, Inc.]
Press Release

European Commission Grants Orphan Medicinal Product Designation for Emmaus Medical’s Sickle Cell Treatment
Emmaus Medical, Inc. announced that the European Commission has granted Orphan Medicinal Product designation for the company’s investigational drug Levoglutamide for the treatment of sickle cell disease. [Emmaus Medical, Inc.] Press Release

Soligenix Announces $600,000 NIAID SBIR Grant Award Supporting Further Evaluation of OrbeShield™ as a Treatment for Acute Radiation Syndrome
Soligenix, Inc. announced that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support further preclinical development of OrbeShield™ as a treatment for gastrointestinal acute radiation syndrome (GI ARS). ARS occurs after toxic radiation exposure and involves several organ systems, notably the bone marrow and the GI tract. [PR Newswire Association LLC] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)
Center for Biologics Evaluation and Research (United States)
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW The 2nd Midwest Conference on Stem Cell Biology and Therapy
October 5-7, 2012
Rochester, United States

Visit our events page to see a complete list of events in the hematopoietic community.


Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Research Technologist – Research and Development (STEMCELL Technologies, Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Postdoctoral Position – Anti-HIV Hematopoietic Stem Cell Gene Therapy (University of California, Los Angeles)

Postdoctoral Position – Hematopoietic Stem Cell Biology and Immunology (University of California, San Francisco)

Postdoctoral Positions – Stem Cells and Immunology (University of Connecticut)

Postdoctoral Position – Stem Cells (Children’s Hospital of Chicago Research Center)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us